Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution?
The review discusses the problem of anticoagulant therapy for the prevention of stroke and systemic embolism in patients with atrial fibrillation and comorbidities (hypertension, heart defects, including after heart valve surgery, coronary artery disease, diabetes mellitus, chronic kidney disease, g...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-01-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4801 |
| _version_ | 1826561057463730176 |
|---|---|
| author | E V Schlyakhto E I Baranova V A Ionin |
| author_facet | E V Schlyakhto E I Baranova V A Ionin |
| author_sort | E V Schlyakhto |
| collection | DOAJ |
| description | The review discusses the problem of anticoagulant therapy for the prevention of stroke and systemic embolism in patients with atrial fibrillation and comorbidities (hypertension, heart defects, including after heart valve surgery, coronary artery disease, diabetes mellitus, chronic kidney disease, gastrointestinal diseases, anemia, cancer), as well as with a high risk of emergency operations and injuries. |
| first_indexed | 2024-04-09T20:43:24Z |
| format | Article |
| id | doaj.art-740b33acade94748932d8fcc019779bd |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2025-03-14T09:26:07Z |
| publishDate | 2022-01-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-740b33acade94748932d8fcc019779bd2025-03-02T11:42:56Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-01-01261210.15829/1560-4071-2021-48013446Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution?E V Schlyakhto0E I Baranova1V A Ionin2Almazov National Medical Research CentreAlmazov National Medical Research Center; Pavlov First Saint Petersburg State Medical UniversityPavlov St-Petersburg State Medical UniversityThe review discusses the problem of anticoagulant therapy for the prevention of stroke and systemic embolism in patients with atrial fibrillation and comorbidities (hypertension, heart defects, including after heart valve surgery, coronary artery disease, diabetes mellitus, chronic kidney disease, gastrointestinal diseases, anemia, cancer), as well as with a high risk of emergency operations and injuries.https://russjcardiol.elpub.ru/jour/article/view/4801atrial fibrillationanticoagulantscomorbidity |
| spellingShingle | E V Schlyakhto E I Baranova V A Ionin Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution? Российский кардиологический журнал atrial fibrillation anticoagulants comorbidity |
| title | Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution? |
| title_full | Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution? |
| title_fullStr | Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution? |
| title_full_unstemmed | Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution? |
| title_short | Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution? |
| title_sort | antithrombotic therapy for atrial fibrillation and comorbidities how to choose the optimal solution |
| topic | atrial fibrillation anticoagulants comorbidity |
| url | https://russjcardiol.elpub.ru/jour/article/view/4801 |
| work_keys_str_mv | AT evschlyakhto antithrombotictherapyforatrialfibrillationandcomorbiditieshowtochoosetheoptimalsolution AT eibaranova antithrombotictherapyforatrialfibrillationandcomorbiditieshowtochoosetheoptimalsolution AT vaionin antithrombotictherapyforatrialfibrillationandcomorbiditieshowtochoosetheoptimalsolution |